RecruitingPhase 1NCT04872790

Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia

Studying Acute lymphoblastic leukemia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
OHSU Knight Cancer Institute
Principal Investigator
Jessica T Leonard
OHSU Knight Cancer Institute
Intervention
Dasatinib(drug)
Enrollment
20 enrolled
Eligibility
18 years · All sexes
Timeline
20222026

Study locations (1)

Collaborators

AbbVie · Oregon Health and Science University

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04872790 on ClinicalTrials.gov

Other trials for Acute lymphoblastic leukemia

Additional recruiting or active studies for the same condition.

See all trials for Acute lymphoblastic leukemia

← Back to all trials